Type 2 diabetes
Conditions
Interventions
non-DPP-i antidiabetic drug group:None
Adding teneligliptin:None
Sponsors
Chengdu Eighth People's Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age =4 weeks; 3. Fasting C-peptide >=1.0 ng/mL; or random C-peptide >=2.0 ng/mL; or a previous oral glucose tolerance test (OGTT) indicating adequate insulin secretion; or HOMA-ß >=30%; 4. Glycated hemoglobin (HbA1c) during the screening period is 7.0%–9.0% (including both endpoints); 5. The participant or their family can understand the procedures and methods of this clinical trial, and after being fully informed, they voluntarily agree to participate and sign the informed consent form themselves or through their family.
Exclusion criteria
Exclusion criteria: 1.Patients with a confirmed diagnosis of type 1 diabetes, specific types of diabetes, or secondary diabetes; 2.Patients with a confirmed history of allergy to DPP-4 inhibitors or a history of allergic reactions; 3.Patients with type 2 diabetes who require concomitant use of a GLP-1 receptor agonist or insulin; 4.Patients who have experienced acute metabolic complications (ketoacidosis, lactic acidosis, or hyperosmolar coma) within the past month; 5.Patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (undergoing dialysis prior to informed consent); 6.Patients with an estimated survival of <14 weeks; 7.Patients with severe infections, those before or after surgery, or those with severe trauma; 8.Patients for whom the investigator believes efficacy cannot be assessed or who are unlikely to complete the intended treatment course and follow-up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Countries
China
Contacts
Public ContactYingfeng Pu
Chengdu Eighth People's Hospital
Outcome results
None listed